Emergent BioSolutions appoints Dr. Kathryn Zoon to board of directors

Global specialty biopharmaceutical company Emergent Biosolutions Inc. has appointed Dr. Kathryn Zoon to its board of directors.

Zoon is currently a Scientist Emeritus of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH).

Zoon’s connection with NIH spans 40 years, and she has been a member of the NIH Board of Scientific Directors since 1992. She also has served on the World Health Organization’s Expert Committee on Biological Standards for nearly 20 years and has been an active member of the National Academy of Medicine since 2002.

In addition, Zoon spent 23 years at the U.S. Food and Drug Administration, where she served as director of the Center for Biologics Evaluation and Research for 10 years, among other positions.

“We are excited to welcome Dr. Zoon as a member of the Emergent BioSolutions Board of Directors,” said Fuad El-Hibri, executive chairman of the board of Emergent BioSolutions.

“As Emergent renews its focus on meeting the medical countermeasure and preparedness needs of the U.S. government, Dr. Zoon’s expertise in regulatory matters and product development will add greater depth and breadth to our diverse board and will be instrumental in helping ensure continued growth for the company,” he said.

Zoon has published 130 scientific studies and has received a number of awards in recognition of her services, performances and capabilities as a scientist.

“I am pleased with this appointment to serve on the board of Emergent BioSolutions, whose corporate mission – to protect and enhance life – aligns with my life’s work and passion for bringing to market medical discoveries that improve the quality of human life,” Zoon said. “I look forward to contributing to Emergent’s success and hope to leverage my experience to assist the management team and the company in achieving their goals.”

Gaithersburg, Maryland-based Emergent BioSolutions develops, manufactures and delivers a variety of medical countermeasures for biological and chemical threats and emerging infectious diseases.